Redx Pharma plc Share Purchase by Directors (3953A)
28 December 2017 - 4:45AM
UK Regulatory
TIDMREDX
RNS Number : 3953A
Redx Pharma plc
27 December 2017
REDX PHARMA PLC
("Redx" or "the Company")
Share Purchases by Directors
Alderley Park, December 27 2017- Redx Pharma (AIM:REDX), the
drug discovery and development company, announces that it has been
notified that Iain Ross, Executive Chairman, has on Friday 22
December acquired 102,000 Redx ordinary shares at a price of 20.75
pence per share. Following this, Mr Ross will hold 450,000 ordinary
shares in the Company, representing 0.36 per cent. of the issued
share capital.
The Company also announces that Non-Executive Director Mr Peter
Presland has on Friday 22 December acquired 120,000 Redx ordinary
shares at a price of 22 pence per share. Mr Presland purchased the
shares through his self-invested personal pension (SIPP). Following
this, Mr Presland will hold 120,000 ordinary shares in the Company,
representing 0.09 per cent of the issued share capital.
The Company also announces that Non-Executive Director Dr
Bernhard Kirschbaum has today acquired 50,000 Redx ordinary shares
at a price of 21 pence per share. Following this, Dr Kirschbaum
will hold 50,000 ordinary shares in the Company, representing 0.04
per cent of the issued share capital.
For further information, please contact:
Redx Pharma Plc T: +44 1625
469 918
Iain Ross, Executive Chairman
Cantor Fitzgerald Europe (Nominated T: +44 20
Advisor & Broker) 7894 7000
Phil Davies
WG Partners LLP (Joint Broker) T: +44 20
3705 9330
Claes Spång/ Chris Lee/ David
Wilson
FTI Consulting T: +44 20
3727 1000
Simon Conway/Stephanie Cuthbert
About Redx Pharma
Redx Pharma discovers and develops proprietary, small molecule
drugs to address areas of high unmet medical need in cancer and
fibrosis. In cancer, Redx pursues targeted therapies where a
biomarker can potentially be used for selecting those patients that
are most likely to benefit from therapy, and/or drugs that are
designed to disrupt cancer resistance pathways. In fibrosis, the
Company is focused on developing treatments that will stop and
reverse the formation of fibrotic tissue. In both therapeutic areas
Redx's aim is to develop drugs whose profile suggests they will be
best in class, if not first in class.
Notification of a Transaction pursuant to Article
19(1) of Regulation (EU) No. 596/2014
---------------------------------------------------------
1 Details of the person discharging managerial
responsibilities/person closely associated
--- ----------------------------------------------------
a. Name Iain Ross
---------------------------
2 Reason for
notification
--- ----------------------- ---------------------------
a. Position/Status Executive Chairman
--- ----------------------- ---------------------------
b. Initial notification/ Initial Notification
Amendment
--- ----------------------- ---------------------------
3 Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
----------------------------------------------------
a. Name Redx Pharma Plc
--- ----------------------- ---------------------------
b. LEI 213800HMS4EBXO589Y37
--- ----------------------- ---------------------------
4 Details of the transaction(s): section to
be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transactions
have been conducted
--- ----------------------------------------------------
a. Description Ordinary Shares of 1p each
of the financial
instrument,
type of instrument
ISIN: GB00BSNB6S51
Identification
Code
--- ----------------------- ---------------------------
b. Nature of the Purchase
transaction
--- ----------------------- ---------------------------
c. Price(s) and 102,000
volume(s)
20.75 pence
--- ----------------------- ---------------------------
d. Aggregated N/A - Single Transaction
information
- Aggregated
Volume
- Price
--- ----------------------- ---------------------------
e. Date of the 22/12/17
transaction
--- ----------------------- ---------------------------
f. Place of the Outside of trading venue
transaction
--- ----------------------- ---------------------------
Notification of a Transaction pursuant to Article
19(1) of Regulation (EU) No. 596/2014
---------------------------------------------------------
1 Details of the person discharging managerial
responsibilities/person closely associated
--- ----------------------------------------------------
a. Name Peter Presland
---------------------------
2 Reason for
notification
--- ----------------------- ---------------------------
a. Position/Status Non-executive Director
--- ----------------------- ---------------------------
b. Initial notification/ Initial Notification
Amendment
--- ----------------------- ---------------------------
3 Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
----------------------------------------------------
a. Name Redx Pharma Plc
--- ----------------------- ---------------------------
b. LEI 213800HMS4EBXO589Y37
--- ----------------------- ---------------------------
4 Details of the transaction(s): section to
be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transactions
have been conducted
--- ----------------------------------------------------
a. Description Ordinary Shares of 1p each
of the financial
instrument,
type of instrument
ISIN: GB00BSNB6S51
Identification
Code
--- ----------------------- ---------------------------
b. Nature of the Purchase
transaction
--- ----------------------- ---------------------------
c. Price(s) and 120,000
volume(s)
22 pence
--- ----------------------- ---------------------------
d. Aggregated N/A - Single Transaction
information
- Aggregated
Volume
- Price
--- ----------------------- ---------------------------
e. Date of the 22/12/17
transaction
--- ----------------------- ---------------------------
f. Place of the Outside of trading venue
transaction
--- ----------------------- ---------------------------
Notification of a Transaction pursuant to Article
19(1) of Regulation (EU) No. 596/2014
---------------------------------------------------------
1 Details of the person discharging managerial
responsibilities/person closely associated
--- ----------------------------------------------------
a. Name Bernhard Kirschbaum
---------------------------
2 Reason for
notification
--- ----------------------- ---------------------------
a. Position/Status Non-executive Director
--- ----------------------- ---------------------------
b. Initial notification/ Initial Notification
Amendment
--- ----------------------- ---------------------------
3 Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
----------------------------------------------------
a. Name Redx Pharma Plc
--- ----------------------- ---------------------------
b. LEI 213800HMS4EBXO589Y37
--- ----------------------- ---------------------------
4 Details of the transaction(s): section to
be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transactions
have been conducted
--- ----------------------------------------------------
a. Description Ordinary Shares of 1p each
of the financial
instrument,
type of instrument
ISIN: GB00BSNB6S51
Identification
Code
--- ----------------------- ---------------------------
b. Nature of the Purchase
transaction
--- ----------------------- ---------------------------
c. Price(s) and 50,000
volume(s)
21 pence
--- ----------------------- ---------------------------
d. Aggregated N/A - Single Transaction
information
- Aggregated
Volume
- Price
--- ----------------------- ---------------------------
e. Date of the 27/12/17
transaction
--- ----------------------- ---------------------------
f. Place of the Outside of trading venue
transaction
--- ----------------------- ---------------------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHOKODQOBDDNBB
(END) Dow Jones Newswires
December 27, 2017 12:45 ET (17:45 GMT)
Redx Pharma (LSE:REDX)
Historical Stock Chart
From Apr 2024 to May 2024
Redx Pharma (LSE:REDX)
Historical Stock Chart
From May 2023 to May 2024